ArticleCommunications biology2018

Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance.

Jemilat Salami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.